Opmax announced that in the first half of 2026, it is expected to achieve operating income of about 450 million yuan, an increase of 153% year on year; net profit attributable to owners of the parent company is expected to be around 124 million yuan, an increase of 229% year on year; net profit after deduction is estimated to be about 49 million yuan, an increase of 64% year on year. The increase in performance was mainly due to the completion of the transfer of assets to Pengli Biotech in January and included in the consolidated statement. Pengli Biotech contributed 220 million yuan in revenue and about 30 million yuan in net profit; the company's original business revenue was 230 million yuan, an increase of more than 30% over the same period last year.

Opmax announced that in the first half of 2026, it is expected to achieve operating income of about 450 million yuan, an increase of 153% year on year; net profit attributable to owners of the parent company is expected to be around 124 million yuan, an increase of 229% year on year; net profit after deduction is estimated to be about 49 million yuan, an increase of 64% year on year. The increase in performance was mainly due to the completion of the transfer of assets to Pengli Biotech in January and included in the consolidated statement. Pengli Biotech contributed 220 million yuan in revenue and about 30 million yuan in net profit; the company's original business revenue was 230 million yuan, an increase of more than 30% over the same period last year.